Objective: Leprosy is a contagious chronic granulomatous disease and commonly affects the eyes and the internal organs. Leprosy can be classified according to the level of immune response. Leprosy is a disease that is associated with defects in cellular immunity. This is why we have investigated the leprosy patients that were referred to our hospital for chronic hepatitis B and C co-infections.
INTRODUCTION
Leprosy is a contagious chronic granulomatous disease that is caused by Mycobacterium leprae, which is also known as Hansen's bacillus and commonly affects the eyes and the internal organs (liver, lymph nodes, bone marrow, and spleen). It is typically spread with aerosols via close contact with the mouth and nose. Incubation period can be as long as two to six years. 1 3 It is a known fact that the incidence of Leprosy is higher in populations of low socioeconomical status, poor hygiene, crowded family surroundings, and poor nutrition. Leprosy has been rarely observed in developed Western countries, but it is still present in our country as well as Middle Africa, Asia, India, some Far East Countries, and Central American Countries. 1 In Turkey, the cumulative number of patients is about 1,044 as determined by the 2014 disease notifications. The majority of these patients has completed treatment and is inactive. The number of patients treated was 21 and the number of patients newly identified in the survey in recent years is approximately six patients. These patients are usually in the environment of older patients (relative) and are long incubation periods.
4
Leprosy can be classified according to the level of immune response. There are two distinct clinical types of the disease known as lepromatous leprosy and tuberculoid leprosy and a borderline form with hybrid characteristics. In lepromatous leprosy, there are nodules called 'leproma' in which ulceration and necrosis can be seen. Ulcers heal slowly and result in atrophic scars and even tissue destructions. Lesions are commonly observed in soft and hard palate, uvula, under the tongue, and on the lips. Moreover, there can be anterior maxillary involvement and tooth loss. Diagnosis depends on clinical suspicion and should be confirmed by bacteriologic and histological analysis. 1, 2 HBV infection is a world-wide health problem. Four hundred million people are chronically infected with HBV and it is estimated that 1 million people a year have HBV-related deaths. 5 The September 2010 hepatitis B technical report of ECDC reported the prevalence of hepatitis B in the general population between 2.0-8.0% in Turkey. 6 In studies of the prevalence of hepatitis B in our country, HBsAg positivity was reported to nearly 10.0%. But in the recent studies, decreasing HBsAg positivity has been detected over the years (from 5.2% to 2.97%). 7 In the Elazığ region, the rate of HbsAg presence was found to be 4.0-10.0%. 8 Anti-HCV positivity was found to be 0.95% in current epidemiological studies, which evaluated 5,471 people between the years 2008 to 2011. 9 In another study, anti-HCV positivity was determined to be 0.9%. 10 There are no studies that present data about the HBsAg and Anti-HCV seroprevalance at leprosy patients in Elazıg.
In a study which was reported from our country, anti-HCV positivity was shown to be 15.2%, HBsAg positivity was determined to be 10.8% and anti-HBs positivity was observed at 50% in leprosy patients. 1 Possible causes include the fact that these patients may refer to hospitals many times. In addition, it is known that individuals with anti-HCV positivity go to the dentist for many dental structures that fracture. The carrier may be higher because the risks remain immune deficient in these patients.
Leprosy is a disease that is associated with defects in cellular immunity. Therefore, sensitivity to co-infections is higher in patients with leprosy.
2 For this reason, we have investigated the leprosy patients referred to our hospital for chronic hepatitis B and C co-infections. We aimed to determine and evaluate HBsAg and Anti-HCV positivity in leprosy patients from our region.
METHODS
Fifty patients who were enrolled and treated in the Leprosy Unit in Elazığ Research and Training hospital between the dates of June-December 2011 for microbiological and pathological investigations were evaluated retrospectively. Data such as patients' age, disease duration, hospitalization duration, education level, and gender were collected prospectively. Blood samples were taken and each patient was for HBV and HCV. A Macro ELISA assay was performed for Hepatitis B, Hepatitis C, and HIV. In patients with HBsAg presence, confirmation was performed by Alisei Quality System -SEAC Micro ELISA. RT-PCR was used to detect levels of HBV DNA and HCV RNA. Presence of Anti-HCV was assessed with a Vitros Immunodiagnostic Products Anti-HCV Reagent Pack macro ELİSA kit (OrthoClinical Diagnostics, Inc). Data was entered into the SPSS 12.0 program and statistically evaluated. in the study. Fourteen of the patients (28.0%) were female and 36 (72.0%) were male. The mean age of the patients was 68 years. One or more hypopigmented multiple erythematous macules, nodules, and/or papules were observed on these patients' skin.
RESULTS

Fifty
We observed loss of sensation in the plaque all of them. Of these patients, 14 (4 females) had tuberculoid leprosy, whereas three (two female) had borderline lepromatous leprosy. The remaining 33 patients (8 female) were diagnosed as having lepromatous leprosy. The average disease duration in tuberculoid, borderline, and lepromatous cases was found to be 39, 35, and 43 years, respectively. HBsAg presence was noted in three of 33 lepromatous leprosy patients and in one of three borderline lepromatous patients. There was no HBsAg presence detected in any of the 14 tuberculoid leprosy patients. A total of 8.0% HBsAg presence was noted. In the lepromatous form, HBsAg seroprevalance was found to be 9.0%. In patients with HBsAg presence, the HBV DNA was searched for and the result was negative in all cases. All four patients that had HBsAg presence also had Anti-HBc presence. Isolated Anti-HBc presence was not encountered in any of the patients.
All 46 patients with negative HBsAg were assessed for Anti-HBs presence and 22 of them (47.0%) were found to have HBs antigens. Twelve of these had lepromatous leprosy, whereas nine had the tuberculoid form and one had the borderline form. In 15 of these 22 patients (68.0%), there was simultaneous Anti-HBc presence in accordance with the previous infection. In the patients in our study, there was 30.0% chronic hepatitis B infection. In only seven patients (31.8%), there was isolated anti-HBs presence related to previous immunization. There was no HBV and HCV co-presence in any of the patients.
Anti-HCV presence was noted in 16 patients. Seven of these were from tuberculoid leprosy patients (50.0%) and nine was from lepromatous leprosy patients (27.2%). Five of these patients were female and 11 were male. There was no HCV antigens detected in any of the borderline lepromatous group of patients. The total rate of anti-HCV presence in the patients was noted to be 32.0%. HCV RNA was sought in patients with anti-HCV presence and in the eight patients. HCV RNA levels were higher than levels that could be detected. Of these eight patients, four were tuberculoid leprosy patients and the remaining four patients had lepromatous leprosy. None of the patients had HIV antigens. 
DISCUSSION
It is known that at least 1/3 of the world's population has somehow been introduced to HBV and has a healed or chronic infection. There are 350 million chronic hepatitis B cases and the HBsAg presence has been reported to be between 2.0% and 8.0% in Turkey and Turkey is in the middle endemic region. 6, 11 There are more than 160 million chronic HCV patients worldwide; however, most are not aware of the disease. This number corresponds approximately to 2.3% of the world's population. Long-term hepatic exposure to HCV leads to progressive fibrosis, cirrhosis, and increases in the hepatocellular carcinoma cases. 12 Co-infections with leprosy, a chronic granulomatous disease, have been under investigation since the 1970s. Hepatitis B and hepatitis C viruses are transmitted by body fluids and generally seropositive and negative individuals share the same environment. This risk has increased in leprosy patients who have been put in the same wards for a long time. In a Rosa et al. 13 study, a fourfold increase was observed in the HBV risk in hospitalized patients compared to non-hospitalized patients. Both infections were detected more in the lepromatous form in accordance with the literature.
J Microbiol Infect Dis www.jmidonline.org Vol 5, No 3, September 2015
In another study, 50.8% of the leprosy patients were found with reactional episodes had HBV and HCV co-infections. The episodes were more frequent in these patients compared with the non-coinfected group. 14 The highest HBV and HCV prevalence is expected in the lepromatous form because lepromatous leprosy is characterized with the Th 2 type immune response. This pattern is also the immune response that affects the decrease in HBV viral depuration. As a result, patients with lepromatous leprosy cannot generate an adequate immune response for HBV clearance, and this makes them vulnerable to co-infections. 15 In our study, three of the four patients with HBsAg presence were patients with lepromatous leprosy. Moreover, nine of the 16 patients with Anti-HCV presence were again patients with lepromatous leprosy and these numbers are in accordance with the previous literature findings.
In studies from Brazil, 25.5% to 39.7% of the patients with leprosy had a positive HBV marker. 15, 16 In Senegal, a study evaluated 987 leprosy patients and revealed similar results (23-25.5%). 17 In our study, we did not encounter any isolated Anti-HBc presence and there was a 47.0% antiHBs presence. In 68.0% of the patients with HBs antigens, there was an accompanying anti-HBc presence as well. In our study group, 30.0% had chronic hepatitis B infection. Only in seven patients (14.0%), there was isolated anti-HBs presence due to previous immunization.
In a Rego et al. 18 study, 620 leprosy patients were evaluated. The patients were most frequently found in borderline patients (48.0%). Presence of hepatitis B or C virus was documented in 9.0%, and all of the patients have reversal reaction.
In another study by Nigam et al 19 , HBsAg screening was performed in 80 leprosy patients and the results were compared with a 50 patient control group. HBsAg presence was 7.5% in leprosy patients and 2.0% in the control group. 19 In our study, HBV seroprevelance was found to be 8.0% in leprosy patients, which is consistent with the previous literature. Another study found the HBsAg seroprevalance to be 6.1-10.0% in lepromatous leprosy patients whereas; this number was between 2.0-5.0% in tuberculoid leprosy patients. 20 In our study, HBsAg seroprevalance in the lepromatous form was 9.0% and in accordance with these findings.
In the literature, the co-infection of leprosy and HBV rate varies between 23.0-39.0%. This difference may be due to the geographic region where the study is held. In our study, 50 leprosy patients of which 66.0% were lepromatous leprosy were assessed and the HBV prevalence was found to be 8.0%.
Our country is in the middle endemicity group with a 2.0-8.0% HBV rate. In various studies held in our country, there was a 4.0-10.0% positivity in HBsAg screening. 7 In Elazığ region, the rate of HBsAg presence was found to be 4.0-10.0% in Elazığ. 8 The rates of our study are in accordance with these findings. Collectively, our results combined with the previous reports are consistent with local endemicity.
Until today, there are studies from Japan and Africa conducted on leprosy patients regarding accompanying anti-HCV presence and the rates in these studies vary between 3.6-9.5%. The 32.0% HCV rate that we encountered in our study is higher than the rates reported previously in the literature. The authors believe that the results of this extremely high rate may be due to higher risk of HCV infection in leprosy patients in our country. In addition, the higher rate of paraphernalia and space common use as well as poor education due to the lower socioeconomical status is conceivable. 1 Rego et al. reported a 5.7% rate of HCV coinfection in leprosy patients with recurring leprosy reactions. 18 As a result of the study, they proposed that HBV and especially HCV are risk factors for recurring leprosy reactions in endemic regions.
In Braga et al. 21 study, the HCV co-infection rate was found to be 3.5% in the 191 leprosy group and 0.15% in the control group. Results were found to be statistically significant. This rate was observed to be increasing in hospitalized patients. The majority of these patients had lepromatous leprosy. It was declared by the authors that the HCV prevalence was increased in leprosy patients. This was especially true in patients that were hospitalized, since precaution had to be taken to prevent HCV transmission in these groups of patients.
However, there are only limited studies in our country regarding leprosy and co-infections. In a Altıparmak et al.
1 study, 46 leprosy patients were assessed. Anti-HCV presence was 15.2%, HBsAg presence was 10.8%, and anti-HBs presence was 50.0%. When our results were compared with this study, we found them to be similar for hepatitis B. But our results for Hepatitis C were higher. The reason for this could be that our study was held in a lower education and sociocultural level region and
